Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma
American Journal of Translational Research · 2026 · 18 (3) · 2483-2488
DOI: 10.62347/gkny9671 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Wensi Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China.
Zitieren
APA
Zhao, W., & Cheng, X. (2026). Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma. American Journal of Translational Research, 18(3), 2483-2488. https://doi.org/10.62347/gkny9671
Vancouver
Zhao W, Cheng X. Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma. American Journal of Translational Research. 2026;18(3):2483-2488. doi:10.62347/gkny9671
BibTeX
@article{Zhao2026,
author = {Zhao, Wensi and Cheng, Xiang},
title = {Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {3},
pages = {2483--2488},
doi = {10.62347/gkny9671}
}
EUVIMED